Lantern Pharma Announces Launch of Antibody Drug Conjugate (ADC) Program to Target Solid Tumors & Blood Cancers through Agreement with Califia Pharma

- Lantern will evaluate and potentially develop ADC programs with novel patent protected linkers, drug payloads and conjugation processes from Califia that have demonstrated enhanced, highly targeted anti-tumor activity, creating new opportunities with Lantern's portfolio of DNA damage compounds - Lantern plans on evaluating and potentially launching additional programs with the ADC compounds and novel linker technologies in cancers where drug resistance is a key issue for both solid-tumors and blood-cancers and there is unmet patient need - Lantern believes that the agreement has the potential to add another key dimension to Lantern's focus on leveraging biological data and innovative platforms to accelerate cancer drug development

Thank you for visiting Tailwinds Research. We are pleased to offer free research on select small and micro cap companies. It is free to join and we hope you’ll take the time to do so.

To create an account please click on this link.

If you already have an account, please log in here.


Please enter your comment!
Please enter your name here